Provided by Tiger Fintech (Singapore) Pte. Ltd.

Gain Therapeutics, Inc.

2.47
+0.09003.78%
Post-market: 2.45-0.0200-0.81%18:13 EDT
Volume:300.98K
Turnover:733.26K
Market Cap:65.52M
PE:-2.28
High:2.53
Open:2.45
Low:2.33
Close:2.38
Loading ...

Gain Therapeutics Price Target Maintained With a $8.00/Share by HC Wainwright & Co.

Dow Jones
·
17 Mar

Gain Therapeutics doses first participant in Phase 1b trial of GT-02287

TIPRANKS
·
14 Mar

Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease

GlobeNewswire
·
14 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
14 Mar

Gain Therapeutics Announces Oral Presentation at AD/PD 2025

GlobeNewswire
·
06 Mar

Gain Therapeutics Advances GT-02287 in Parkinson’s Trials

TIPRANKS
·
07 Feb

Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update

THOMSON REUTERS
·
06 Feb

Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update

GlobeNewswire
·
06 Feb

Gain Therapeutics To Participate in Upcoming Investor Conferences

GlobeNewswire
·
05 Feb

All You Need to Know About Gain Therapeutics (GANX) Rating Upgrade to Strong Buy

Zacks
·
17 Jan

BRIEF-Gain Therapeutics Forms Clinical Advisory Board To Support Continued Advancement Of Lead Drug Candidate GT-02287

Reuters
·
08 Jan

Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287

THOMSON REUTERS
·
08 Jan

Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287

GlobeNewswire
·
08 Jan

Gain Therapeutics Appoints New CEO Amidst Clinical Progress

TIPRANKS
·
08 Jan

Gain Therapeutics appoints Mack as CEO, Director

TIPRANKS
·
07 Jan

Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director

THOMSON REUTERS
·
07 Jan